The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated Mechanism

  title={The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated Mechanism},
  author={Daniela Sarnataro and Simona Pisanti and Antonietta Santoro and Patrizia Gazzerro and Anna Maria Malfitano and Chiara Laezza and Maurizio Bifulco},
  journal={Molecular Pharmacology},
  pages={1298 - 1306}
The endocannabinoid system has been shown to modulate key cell-signaling pathways involved in cancer cell growth. In this study, we show that cannabinoid receptor type 1 (CB1) antagonist Rimonabant (SR141716) inhibited human breast cancer cell proliferation, being more effective in highly invasive metastatic MDA-MB-231 cells than in less-invasive T47D and MCF-7 cells. The SR141716 antiproliferative effect was not accompanied by apoptosis or necrosis and was characterized by a G1/S-phase cell… 

Figures from this paper

Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent

The results of this work characterize the actions of a CB2-selective agonist on breast cancer cells in a syngeneic murine model representing how a clinical presentation of cancer progression and metastasis may be significantly modulated by a G-protein-coupled receptor.

Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells.

  • S. CarpiS. Fogli P. Nieri
  • Biology
    Toxicology in vitro : an international journal published in association with BIBRA
  • 2017

Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

The findings suggest that the combined synergic effect of SR141716 and oxaliplatin improves the blocking of colon cancer cell proliferation and merits further explorations in preclinical and clinical settings.

The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB1 Cannabinoid Receptor

MAGL inhibition led to a CB1-dependent decrease in human lung cancer cell invasion and metastasis via inhibition of 2-AG degradation, with TIMP-1 identified as a mediator of the anti-invasive effect.

JunD is involved in the antiproliferative effect of Δ9-tetrahydrocannabinol on human breast cancer cells

This is the first report showing not only that cannabinoids regulate JunD but, more generally, that JunD activation reduces the proliferation of cancer cells, which points to a new target to inhibit breast cancer progression.

Synthetic Cannabinoids Influence the Invasion of Glioblastoma Cell Lines in a Cell- and Receptor-Dependent Manner

Cannabinoids can influence glioblastoma cell invasion in a receptor and cell type specific manner that is independent of proliferation and apoptosis, and can potentially be used in the future as an addition to current therapy.

A novel chemical inhibitor suppresses breast cancer cell growth and metastasis through inhibiting HPIP oncoprotein

Genome-wide RNA sequencing indicated that TXX-1-10 has more significant effects on regulation of the expression of genes related to DNA replication, cell cycle, apoptosis, cell adhesion, cell migration, and invasion than rimonabant, and HPIP inhibition may be a useful strategy for cancer treatment.



Anandamide inhibits adhesion and migration of breast cancer cells.

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

The data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous Prolactin action at the level of prolactin receptor.

Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation1.

It is reported that β-NGF-induced HBCC proliferation was potently inhibited by the synthetic cannabinoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but not by the an andamide congener, palmitoylethanolamide, or the selective agonist of CB2 cannabinoid receptors, BML-190.

A new strategy to block tumor growth by inhibiting endocannabinoid inactivation

Findings indicate that endocannabinoids tonically control tumor growth in vivo by both CB1‐mediated and non‐CB1‐ mediated mechanisms and that, irrespective of the molecular mechanism of their anti‐proliferative action, inhibitors of their inactivation might be used for the development of novel anti‐cancer drugs.

Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

The findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential negative effectors of PRL- and NGF-induced biological responses, at least in some cancer cells.

Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis

The findings indicate that CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis.

The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A Preadipocytes

Results suggest that inhibition of MAP kinase activity by rimonabant may be one of mechanisms involved in the inhibition of 3T3 F442A preadipocyte cell proliferation and stimulation of adiponectin and GAPDH expression.

Control by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth

  • M. BifulcoC. Laezza V. Di Marzo
  • Biology, Medicine
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2001
The data suggest that Met‐F‐AEA inhibits ras oncogene‐dependent tumor growth in vivo through CB1 cannabinoid receptors; and responsiveness of FRTL‐5 cells to endocannabinoids depends on whether or not they are transformed by K‐ras.

A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1

Chinese hamster ovary cells transfected with human central cannabinoid receptor (CB1) exhibit high constitutive activity at both levels of mitogen-activated protein kinase (MAPK) and adenylyl cyclase, and the CB1-selective ligand, SR 141716A, that functions as an inverse agonist is proposed as a novel model for receptor/ligand interactions.